Global Actinic Keratosis Treatment Market Size, Share, Trends, Industry Growth by Therapy (Topical, Surgery, Laser, Photodynamic Therapy, Others), by Topical Medication (Fluorouracil, Imiquimod, Diclofenac, IngenolMebutate, Others), by Drug Class, by End-Use, by Region, and Forecast to 2027
Report ID: RCMA139 | Report Format: PDF + Excel | Starting Price: 2680/- USD |The global actinic keratosis treatment market size is expected to witness a significant CAGR of over 4% during the forecast period 2021 to 2027. The rising prevalence of actinic keratosis around the world coupled with the rising awareness of its negative effects is a primary factor to drive the market. As per the latest information shared by the Skin Cancer Foundation, it is estimated that 1 in 5 Americans will develop skin cancer by the age of 70 years in the United States. Furthermore, the growing geriatric population globally, increasing government initiatives, and the increasing prevalence rate of the disease in Australia is further anticipated to fuel the market over the forecast period.
Market Segment Insights:
By therapy, the surgery segment dominated the global actinic keratosis treatment market
The global actinic keratosis treatment market is bifurcated into therapy, topical medication, drug class, end-use, and geography. On the basis of therapy, the market is further segmented into topical, surgery, laser, photodynamic therapy, and others. The surgery segment dominated the global market in 2020 and is expected to hold the largest revenue share of around two-third of the market by the end of the analysis period. The increasing adoption of cryotherapy to treat actinic keratosis is a major factor to drive the segment growth. On the flip side, the topical segment is accounted to register the fastest growth rate over the forecast period.
By drug class, the nucleoside metabolic inhibitor segment held the largest market share
On the basis of drug class, the market is segmented into nucleoside metabolic inhibitors, NSAIDs, immune response modifiers, photo enhancers, and others. The nucleoside metabolic inhibitor segment dominated the global actinic keratosis treatment market in 2020 and accounted to hold the largest market share of around one-third of the market in terms of revenue. On the other hand, the photo enhancers segment is expected to grow at the highest growth rate over the forecast period. The increasing adoption of photo enhancers such as metvix, levulan, and others is a major factor to drive the segment growth.
To know more about the study, request sample papers
The actinic keratosis treatment comprehensive study analyzes industry trends, market size, competitive analysis, and market forecast – 2021 to 2027. Research Corridor report provides detailed premium insight into the global market and reveals the potential revenue streams, commercial prospects, market drivers, challenges, opportunities, issues, and events affecting the industry. In addition, the report has a dedicated section covering market forecasts and analysis for leading geographies, profiles of major companies operating in the market and expert opinion obtained from interviews with industry executives and experts from prominent companies.
Historical & Forecast Period
- 2018-19 – Historical Year
- 2020 – Base Year
- 2021-2027 – Forecast Period
Global Actinic Keratosis Treatment Market Segmentation:
Actinic Keratosis Treatment Market Segmentation by Therapy:
- Topical
- Surgery
- Laser
- Photodynamic Therapy
- Others
Actinic Keratosis Treatment Market Segmentation by Topical Medication:
- Fluorouracil
- Imiquimod
- Diclofenac
- IngenolMebutate
- Others
Actinic Keratosis Treatment Market Segmentation by Drug Class:
- Nucleoside Metabolic Inhibitor
- NSAIDs
- Immune Response Modifiers
- Photo enhancers
- Others
Actinic Keratosis Treatment Market Segmentation by End-Use:
- Hospitals
- Private Clinics
- Homecare
- Others
Actinic Keratosis Treatment Market Segmentation by Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Actinic Keratosis Treatment Market: Geographic Coverage
North America is expected to hold the largest revenue share of the global actinic keratosis treatment market by the end of the analysis period
Geographically, North America dominated the global actinic keratosis treatment market in 2020 and is expected to hold the largest revenue share of over one-third of the market by the end of the analysis period. The increasing prevalence of the disease and the rising awareness among consumers are some of the prominent factors to drive the market growth in the region. Furthermore, technological advancement, rising government initiatives and the availability of well-structured healthcare infrastructure are further expected to support the market growth positively. On the flip side, the APAC is expected to register the fastest growth rate over the forecast period due to the increasing treatment facilities and the high prevalence in some countries.
Actinic Keratosis Treatment Market: Competitive Assessment
Some of the major market players operating in the global actinic keratosis treatment market are 3MStanford Chemicals., Sun Pharmaceutical Industries Ltd., Alma Lasers, Bausch Health Companies Inc., and Novartis AG. Companies are exploring markets by expansion, new investment, the introduction of new services, and collaboration as their preferred strategies. Players are exploring new geography through expansion and acquisition to gain a competitive advantage through joint synergy.
List of Key Companies:
- 3MStanford Chemicals.
- Sun Pharmaceutical Industries Ltd
- Alma Lasers
- Bausch Health Companies Inc.
- Novartis AG
- Almirall, LLC
- Biofrontera
- Cipher Pharmaceuticals Inc.
- GlaxoSmithKline plc.
- LEO Pharma Inc.
Key Questions Answered by Actinic Keratosis Treatment Market Report
- Global actinic keratosis treatment market forecasts from 2021-2027
- Regional actinic keratosis treatment market forecasts from 2021-2027 covering Asia-Pacific, North America, Europe, Middle East & Africa, and Latin America
- Country-level forecasts from 2021-2027 covering 15 major countries from the regions as mentioned above
- Actinic keratosis treatment submarket forecasts from 2021-2027 covering the market by therapy, by topical medication, by drug class, by end-use, and geography
- Various industry models such as SWOT analysis, Value Chain Analysis about actinic keratosis treatment market
- Analysis of the key factors driving and restraining the growth of the global, regional, and country-level actinic keratosis treatment markets from 2021-2027
- Competitive Landscape and market positioning of top 10 players operating in the actinic keratosis treatment market
1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.4. Assumptions
2. Executive Summary
2.1. Global Actinic Keratosis Treatment Market Portraiture
2.2. Global Actinic Keratosis Treatment Market, by Therapy, 2020 (USD Mn)
2.3. Global Actinic Keratosis Treatment Market, by Topical Medication, 2020 (USD Mn)
2.4. Global Actinic Keratosis Treatment Market, by Drug Class, 2020 (USD Mn)
2.5. Global Actinic Keratosis Treatment Market, by End-Use, 2020 (USD Mn)
2.6. Global Actinic Keratosis Treatment Market, by Geography, 2020 (USD Mn)
3. Global Actinic Keratosis Treatment Market Analysis
3.1. Actinic Keratosis Treatment Market Overview
3.2. Market Inclination Insights
3.3. Market Dynamics
3.3.1. Drivers
3.3.2. Challenges
3.3.3. Opportunities
3.4. Attractive Investment Proposition
3.5. Competitive Analysis
3.6. Porter’s Five Force Analysis
3.6.1. Bargaining Power of Suppliers
3.6.2. Bargaining Power of Buyers
3.6.3. Threat of New Entrants
3.6.4. Threat of Substitutes
3.6.5. Degree of Competition
3.7. COVID-19 Impact Analysis
4. Global Actinic Keratosis Treatment Market By Therapy, 2018 – 2027 (USD Mn)
4.1. Overview
4.2. Topical
4.3. Surgery
4.4. Laser
4.5. Photodynamic Therapy
4.6. Others
5. Global Actinic Keratosis Treatment Market By Topical Medication, 2018 – 2027 (USD Mn)
5.1. Overview
5.2. Fluorouracil
5.3. Imiquimod
5.4. Diclofenac
5.5. IngenolMebutate
5.6. Others
6. Global Actinic Keratosis Treatment Market By Drug Class, 2018 – 2027 (USD Mn)
6.1. Overview
6.2. Nucleoside Metabolic Inhibitor
6.3. NSAIDs
6.4. Immune Response Modifiers
6.5. Photo enhancers
6.6. Others
7. Global Actinic Keratosis Treatment Market By End-Use, 2018 – 2027 (USD Mn)
7.1. Overview
7.2. Hospitals
7.3. Private Clinics
7.4. Homecare
7.5. Others
8. North America Actinic Keratosis Treatment Market Analysis and Forecast, 2018 – 2027 (USD Mn)
8.1.1. Overview
8.1.2. North America Actinic Keratosis Treatment Market by Therapy (2018-2027 USD Mn)
8.1.3. North America Actinic Keratosis Treatment Market by Topical Medication (2018-2027 USD Mn)
8.1.4. North America Actinic Keratosis Treatment Market by Drug Class (2018-2027 USD Mn)
8.1.5. North America Actinic Keratosis Treatment Market by End-Use (2018-2027 USD Mn)
8.1.6. North America Actinic Keratosis Treatment Market by Country (2018-2027 USD Mn)
8.1.6.1. U.S.
8.1.6.1.1. U.S. Actinic Keratosis Treatment Market by Therapy (2018-2027 USD Mn)
8.1.6.1.2. U.S. Actinic Keratosis Treatment Market by Topical Medication (2018-2027 USD Mn)
8.1.6.1.3. U.S. Actinic Keratosis Treatment Market by Drug Class (2018-2027 USD Mn)
8.1.6.1.4. U.S. Actinic Keratosis Treatment Market by End-Use (2018-2027 USD Mn)
8.1.6.2. Canada
8.1.6.2.1. Canada Actinic Keratosis Treatment Market by Therapy (2018-2027 USD Mn)
8.1.6.2.2. Canada Actinic Keratosis Treatment Market by Topical Medication (2018-2027 USD Mn)
8.1.6.2.3. Canada Actinic Keratosis Treatment Market by Drug Class (2018-2027 USD Mn)
8.1.6.2.4. Canada Actinic Keratosis Treatment Market by End-Use (2018-2027 USD Mn)
9. Europe Actinic Keratosis Treatment Market Analysis and Forecast, 2018 – 2027 (USD Mn)
9.1.1. Overview
9.1.2. Europe Actinic Keratosis Treatment Market by Therapy (2018-2027 USD Mn)
9.1.3. Europe Actinic Keratosis Treatment Market by Topical Medication (2018-2027 USD Mn)
9.1.4. Europe Actinic Keratosis Treatment Market by Drug Class (2018-2027 USD Mn)
9.1.5. Europe Actinic Keratosis Treatment Market by End-Use (2018-2027 USD Mn)
9.1.6. Europe Actinic Keratosis Treatment Market by Country (2018-2027 USD Mn)
9.1.6.1. Germany
9.1.6.1.1. Germany Actinic Keratosis Treatment Market by Therapy (2018-2027 USD Mn)
9.1.6.1.2. Germany Actinic Keratosis Treatment Market by Topical Medication (2018-2027 USD Mn)
9.1.6.1.3. Germany Actinic Keratosis Treatment Market by Drug Class (2018-2027 USD Mn)
9.1.6.1.4. Germany Actinic Keratosis Treatment Market by End-Use (2018-2027 USD Mn)
9.1.6.2. U.K.
9.1.6.2.1. U.K. Actinic Keratosis Treatment Market by Therapy (2018-2027 USD Mn)
9.1.6.2.2. U.K. Actinic Keratosis Treatment Market by Topical Medication (2018-2027 USD Mn)
9.1.6.2.3. U.K. Actinic Keratosis Treatment Market by Drug Class (2018-2027 USD Mn)
9.1.6.2.4. U.K. Actinic Keratosis Treatment Market by End-Use (2018-2027 USD Mn)
9.1.6.3. France
9.1.6.3.1. France Actinic Keratosis Treatment Market by Therapy (2018-2027 USD Mn)
9.1.6.3.2. France Actinic Keratosis Treatment Market by Topical Medication (2018-2027 USD Mn)
9.1.6.3.3. France Actinic Keratosis Treatment Market by Drug Class (2018-2027 USD Mn)
9.1.6.3.4. France Actinic Keratosis Treatment Market by End-Use (2018-2027 USD Mn)
9.1.6.4. Italy
9.1.6.4.1. Italy Actinic Keratosis Treatment Market by Therapy (2018-2027 USD Mn)
9.1.6.4.2. Italy Actinic Keratosis Treatment Market by Topical Medication (2018-2027 USD Mn)
9.1.6.4.3. Italy Actinic Keratosis Treatment Market by Drug Class (2018-2027 USD Mn)
9.1.6.4.4. Italy Actinic Keratosis Treatment Market by End-Use (2018-2027 USD Mn)
9.1.6.5. Rest of Europe
9.1.6.5.1. Rest of Europe Actinic Keratosis Treatment Market by Therapy (2018-2027 USD Mn)
9.1.6.5.2. Rest of Europe Actinic Keratosis Treatment Market by Topical Medication (2018-2027 USD Mn)
9.1.6.5.3. Rest of Europe Actinic Keratosis Treatment Market by Drug Class (2018-2027 USD Mn)
9.1.6.5.4. Rest of Europe Actinic Keratosis Treatment Market by End-Use (2018-2027 USD Mn)
10. Asia Pacific Actinic Keratosis Treatment Market Analysis and Forecast, 2018 – 2027 (USD Mn)
10.1.1. Overview
10.1.2. Asia Pacific Actinic Keratosis Treatment Market by Therapy (2018-2027 USD Mn)
10.1.3. Asia Pacific Actinic Keratosis Treatment Market by Topical Medication (2018-2027 USD Mn)
10.1.4. Asia Pacific Actinic Keratosis Treatment Market by Drug Class (2018-2027 USD Mn)
10.1.5. Asia Pacific Actinic Keratosis Treatment Market by End-Use (2018-2027 USD Mn)
10.1.6. Asia Pacific Actinic Keratosis Treatment Market by Country (2018-2027 USD Mn)
10.1.6.1. China
10.1.6.1.1. China Actinic Keratosis Treatment Market by Therapy (2018-2027 USD Mn)
10.1.6.1.2. China Actinic Keratosis Treatment Market by Topical Medication (2018-2027 USD Mn)
10.1.6.1.3. China Actinic Keratosis Treatment Market by Drug Class (2018-2027 USD Mn)
10.1.6.1.4. China Actinic Keratosis Treatment Market by End-Use (2018-2027 USD Mn)
10.1.6.2. Japan
10.1.6.2.1. Japan Actinic Keratosis Treatment Market by Therapy (2018-2027 USD Mn)
10.1.6.2.2. Japan Actinic Keratosis Treatment Market by Topical Medication (2018-2027 USD Mn)
10.1.6.2.3. Japan Actinic Keratosis Treatment Market by Drug Class (2018-2027 USD Mn)
10.1.6.2.4. Japan Actinic Keratosis Treatment Market by End-Use (2018-2027 USD Mn)
10.1.6.3. Australia
10.1.6.3.1. Australia Actinic Keratosis Treatment Market by Therapy (2018-2027 USD Mn)
10.1.6.3.2. Australia Actinic Keratosis Treatment Market by Topical Medication (2018-2027 USD Mn)
10.1.6.3.3. Australia Actinic Keratosis Treatment Market by Drug Class (2018-2027 USD Mn)
10.1.6.3.4. Australia Actinic Keratosis Treatment Market by End-Use (2018-2027 USD Mn)
10.1.6.4. Rest of Asia Pacific
10.1.6.4.1. Rest of Asia Pacific Actinic Keratosis Treatment Market by Therapy (2018-2027 USD Mn)
10.1.6.4.2. Rest of Asia Pacific Actinic Keratosis Treatment Market by Topical Medication (2018-2027 USD Mn)
10.1.6.4.3. Rest of Asia Pacific Actinic Keratosis Treatment Market by Drug Class (2018-2027 USD Mn)
10.1.6.4.4. Rest of Asia Pacific Actinic Keratosis Treatment Market by End-Use (2018-2027 USD Mn)
11. Latin America (LATAM) Actinic Keratosis Treatment Market Analysis and Forecast, 2018 – 2027 (USD Mn)
11.1.1. Overview
11.1.2. Latin America Actinic Keratosis Treatment Market by Therapy (2018-2027 USD Mn)
11.1.3. Latin America Actinic Keratosis Treatment Market by Topical Medication (2018-2027 USD Mn)
11.1.4. Latin America Actinic Keratosis Treatment Market by Drug Class (2018-2027 USD Mn)
11.1.5. Latin America Actinic Keratosis Treatment Market by End-Use (2018-2027 USD Mn)
11.1.6. Latin America Actinic Keratosis Treatment Market by Country (2018-2027 USD Mn)
11.1.6.1. Brazil
11.1.6.1.1. Brazil Actinic Keratosis Treatment Market by Therapy (2018-2027 USD Mn)
11.1.6.1.2. Brazil Actinic Keratosis Treatment Market by Topical Medication (2018-2027 USD Mn)
11.1.6.1.3. Brazil Actinic Keratosis Treatment Market by Drug Class (2018-2027 USD Mn)
11.1.6.1.4. Brazil Actinic Keratosis Treatment Market by End-Use (2018-2027 USD Mn)
11.1.6.2. Mexico
11.1.6.2.1. Mexico Actinic Keratosis Treatment Market by Therapy (2018-2027 USD Mn)
11.1.6.2.2. Mexico Actinic Keratosis Treatment Market by Topical Medication (2018-2027 USD Mn)
11.1.6.2.3. Mexico Actinic Keratosis Treatment Market by Drug Class (2018-2027 USD Mn)
11.1.6.2.4. Mexico Actinic Keratosis Treatment Market by End-Use (2018-2027 USD Mn)
11.1.6.3. Rest of Latin America
11.1.6.3.1. Rest of Latin America Actinic Keratosis Treatment Market by Therapy (2018-2027 USD Mn)
11.1.6.3.2. Rest of Latin America Actinic Keratosis Treatment Market by Topical Medication (2018-2027 USD Mn)
11.1.6.3.3. Rest of Latin America Actinic Keratosis Treatment Market by Drug Class (2018-2027 USD Mn)
11.1.6.3.4. Rest of Latin America Actinic Keratosis Treatment Market by End-Use (2018-2027 USD Mn)
12. Middle East and Africa Actinic Keratosis Treatment Market Analysis and Forecast, 2018 – 2027 (USD Mn)
12.1.1. Overview
12.1.2. MEA Actinic Keratosis Treatment Market by Therapy (2018-2027 USD Mn)
12.1.3. MEA Actinic Keratosis Treatment Market by Topical Medication (2018-2027 USD Mn)
12.1.4. MEA Actinic Keratosis Treatment Market by Drug Class (2018-2027 USD Mn)
12.1.5. MEA Actinic Keratosis Treatment Market by End-Use (2018-2027 USD Mn)
12.1.6. Middle East and Africa Actinic Keratosis Treatment Market, by Country (2018-2027 USD Mn)
12.1.6.1. GCC
12.1.6.1.1. GCC Actinic Keratosis Treatment Market by Therapy (2018-2027 USD Mn)
12.1.6.1.2. GCC Actinic Keratosis Treatment Market by Topical Medication (2018-2027 USD Mn)
12.1.6.1.3. GCC Actinic Keratosis Treatment Market by Drug Class (2018-2027 USD Mn)
12.1.6.1.4. GCC Actinic Keratosis Treatment Market by End-Use (2018-2027 USD Mn)
12.1.6.2. South Africa
12.1.6.2.1. South Africa Actinic Keratosis Treatment Market by Therapy (2018-2027 USD Mn)
12.1.6.2.2. South Africa Actinic Keratosis Treatment Market by Topical Medication (2018-2027 USD Mn)
12.1.6.2.3. South Africa Actinic Keratosis Treatment Market by Drug Class (2018-2027 USD Mn)
12.1.6.2.4. South Africa Actinic Keratosis Treatment Market by End-Use (2018-2027 USD Mn)
12.1.6.3. Rest of MEA
12.1.6.3.1. Rest of MEA Actinic Keratosis Treatment Market by Therapy (2018-2027 USD Mn)
12.1.6.3.2. Rest of MEA Actinic Keratosis Treatment Market by Topical Medication (2018-2027 USD Mn)
12.1.6.3.3. Rest of MEA Actinic Keratosis Treatment Market by Drug Class (2018-2027 USD Mn)
12.1.6.3.4. Rest of MEA Actinic Keratosis Treatment Market by End-Use (2018-2027 USD Mn)
13. Company Profiles
13.1. 3MStanford Chemicals
13.1.1. Business Description
13.1.2. Financial Health and Budget Allocation
13.1.3. Product Positions/Portfolio
13.1.4. Recent Development
13.1.5. SWOT Analysis
13.2. Sun Pharmaceutical Industries Ltd.
13.2.1. Business Description
13.2.2. Financial Health and Budget Allocation
13.2.3. Product Positions/Portfolio
13.2.4. Recent Development
13.2.5. SWOT Analysis
13.3. Alma Lasers
13.3.1. Business Description
13.3.2. Financial Health and Budget Allocation
13.3.3. Product Positions/Portfolio
13.3.4. Recent Development
13.3.5. SWOT Analysis
13.4. Bausch Health Companies Inc.
13.4.1. Business Description
13.4.2. Financial Health and Budget Allocation
13.4.3. Product Positions/Portfolio
13.4.4. Recent Development
13.4.5. SWOT Analysis
13.5. Novartis AG
13.5.1. Business Description
13.5.2. Financial Health and Budget Allocation
13.5.3. Product Positions/Portfolio
13.5.4. Recent Development
13.5.5. SWOT Analysis
13.6. Almirall, LLC
13.6.1. Business Description
13.6.2. Financial Health and Budget Allocation
13.6.3. Product Positions/Portfolio
13.6.4. Recent Development
13.6.5. SWOT Analysis
13.7. Biofrontera
13.7.1. Business Description
13.7.2. Financial Health and Budget Allocation
13.7.3. Product Positions/Portfolio
13.7.4. Recent Development
13.7.5. SWOT Analysis
13.8. Cipher Pharmaceuticals Inc.
13.8.1. Business Description
13.8.2. Financial Health and Budget Allocation
13.8.3. Product Positions/Portfolio
13.8.4. Recent Development
13.8.5. SWOT Analysis
13.9. GlaxoSmithKline plc.
13.9.1. Business Description
13.9.2. Financial Health and Budget Allocation
13.9.3. Product Positions/Portfolio
13.9.4. Recent Development
13.9.5. SWOT Analysis
13.10. LEO Pharma Inc.
13.10.1. Business Description
13.10.2. Financial Health and Budget Allocation
13.10.3. Product Positions/Portfolio
13.10.4. Recent Development
13.10.5. SWOT Analysis
$ 4800/- Multi User License $ 6800/- Corporate License

- Markets in over 100+ countries analyzed granularly
- 35% of our total client are returning clients
- 1000+ customers globally
- 100+ paid data sources mined to bring cutting-edge insights
- 24x5 availability - we are always there when you need us
- "Free of Cost Report Customization" is available
- Request a regional report at Best Price
- Our expert team will assist you with all research need and customization
- Our expert research analysts will resolve your every query before and after purchasing the report
